INDEX OF GENOMIC EXPRESSION OF ESTROGEN RECEPTOR (ER) AND ER-RELATED GENES
    8.
    发明申请
    INDEX OF GENOMIC EXPRESSION OF ESTROGEN RECEPTOR (ER) AND ER-RELATED GENES 审中-公开
    雌激素受体(ER)和ER相关基因的基因表达指数

    公开(公告)号:US20100311601A1

    公开(公告)日:2010-12-09

    申请号:US12772816

    申请日:2010-05-03

    IPC分类号: C12Q1/68 C40B30/02

    摘要: The present invention provides the identification and combination of genes that are expressed in tumors that are responsive to a given therapeutic agent and whose combined expression can be used as an index that correlates with responsiveness to that therapeutic agent. One or more of the genes of the present invention may be used as markers (or surrogate markers) to identify tumors that are likely to be successfully treated by that agent or class of agents such as hormonal or endocrine therapy or chemotherapy.

    摘要翻译: 本发明提供了在对给定治疗剂有反应的肿瘤中表达的基因的鉴定和组合,并且其组合表达可用作与对该治疗剂的反应性相关的指标。 本发明的一个或多个基因可用作标志物(或替代标记物),以鉴定可能由该试剂或类别的试剂例如激素或内分泌治疗或化学疗法成功治疗的肿瘤。

    Bifunctional Predictors of Cancer Treatment Sensitivity and Resistance
    10.
    发明申请
    Bifunctional Predictors of Cancer Treatment Sensitivity and Resistance 审中-公开
    癌症治疗敏感性和抗性的双功能预测因子

    公开(公告)号:US20100178651A1

    公开(公告)日:2010-07-15

    申请号:US12513338

    申请日:2007-11-05

    IPC分类号: C12Q1/68 G01N33/574

    摘要: The present invention provides the identification of genes that are expressed in tumors to indicate responsiveness or resistance to an agent or class of agents. More particularly, these genes show expression associated with responsiveness to one agent or class of agents is inversely related to expression in association with another class of agents. One or more of theses genes of the present invention can be used as markers (or surrogate markers) to identify tumors that are likely to be successfully treated by the responsive agent as well as to identify tumors that should avoid treatment by the resistant agent.

    摘要翻译: 本发明提供了在肿瘤中表达的基因的鉴定,以指示对试剂或试剂类的反应性或抗性。 更具体地说,这些基因表现出与一种药剂的反应性相关的表达或与另一类药剂相关的表达是负相关的。 本发明的一个或多个这些基因可以用作标记物(或替代标记物)来鉴定可能被响应剂成功治疗的肿瘤以及鉴定应该避免被抗药剂治疗的肿瘤。